stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Current ratio
Tango Therapeutics, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 50.8×, up 34.5× from fiscal 2025 (16.3×). Over the past ten years it has ranged from 4.7× (fiscal 2020) to 16.3× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 16.3× | 133.85% |
| FY2024 | 7.0× | (7.50%) |
| FY2023 | 7.5× | 11.65% |
| FY2022 | 6.8× | (44.16%) |
| FY2021 | 12.1× | 155.68% |
| FY2020 | 4.7× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 50.8× | 85.64% |
| Mar 2026 | 27.4× | 67.78% |
| Dec 2025 | 16.3× | 83.76% |
| Sep 2025 | 8.9× | 86.96% |
| 21 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| TNGX Tango Therapeutics, Inc. | 50.8× |
| IRON Disc Medicine, Inc. compare | 24.1× |
| XENE Xenon Pharmaceuticals Inc. compare | 21.0× |
| RLAY Relay Therapeutics, Inc. compare | 18.3× |
| PBLS Parabilis Medicines, Inc. compare | 17.9× |
| EWTX Edgewise Therapeutics, Inc. compare | 16.2× |
| ABCL AbCellera Biologics Inc. compare | 12.8× |
| IOVA Iovance Biotherapeutics, Inc. compare | 5.2× |
| ACAD ACADIA Pharmaceuticals Inc. compare | 3.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement